Regeneron Advances Melanoma Treatment with New Phase 2 Trial

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals has initiated a Phase 2 clinical trial titled ‘A Phase 2 Peri-operative Trial of Fianlimab and Cemiplimab Compared With Anti-PD1 Alone in Patients With Resectable Stage III and IV Melanoma.’ The study aims to evaluate the safety and efficacy of combining fianlimab with cemiplimab versus cemiplimab alone in treating high-risk, resectable melanoma. This research is significant as it explores potential advancements in immunotherapy for melanoma, a serious form of skin cancer.

The trial is testing an experimental drug, fianlimab, in combination with cemiplimab, both of which are immune checkpoint inhibitors. These drugs are designed to help the immune system identify and destroy cancer cells more effectively.

The study is interventional, with a randomized, parallel assignment model. It employs triple masking, meaning the participant, care provider, and investigator are unaware of the treatment allocations. The primary purpose of the study is treatment-focused.

The study began on September 18, 2024, with an estimated primary completion date and overall completion date yet to be announced. The last update was submitted on July 14, 2025, indicating ongoing progress.

This update could positively influence Regeneron’s stock performance and investor sentiment, as successful outcomes may enhance the company’s position in the competitive immunotherapy market. Investors should monitor this study’s developments closely, considering the potential impact on the broader industry.

The study is currently recruiting, with further details available on the ClinicalTrials portal.